Please assess the completion status of the following clinical trial:

Trial Title: Understanding Disparities in Quitting in African American and White Smokers

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Non-Hispanic African American or non-Hispanic White~* ≥ 18 years of age~* Smoked 3-20 cigarettes per day~* Smoked on \>25 days of the past 30 days~* Functioning telephone~* Interested in quitting smoking~* Interested in taking 3 months of varenicline~* Willing to complete all study visits~Exclusion Criteria:~* Renal impairment~* Evidence or history of clinically significant allergic reactions to varenicline~* A cardiovascular event in the past month Hospitalization in the past 2 months for any cardiovascular disease, including but not limited to:~  * Angina~ * Myocardial infarction~ * Peripheral vascular disease~ * Stroke~* New onset of chest pain or arrhythmia in the past 2 months~* History of alcohol or drug dependency in the past year~* Major depressive disorder in the last year requiring treatment~* History of panic disorder, psychosis, bipolar disorder, or eating disorders~* Use of tobacco products other than cigarettes in past 30 days~* Use of pharmacotherapy in the month prior to enrollment, including prior use of varenicline~* Pregnant, contemplating getting pregnant, or breastfeeding~* Plans to move from Kansas City during the treatment and follow-up phase~* Another household member enrolled in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- African American (AA) Smokers (Type: EXPERIMENTAL): AA smokers received 12 weeks of Varenicline and 6 smoking cessation counseling sessions.
- White Smokers (Type: ACTIVE_COMPARATOR): White smokers received 12 weeks of Varenicline and 6 smoking cessation counseling sessions.

Based on this trial design, predict the completion outcome and termination type (if applicable).